Actively Recruiting
Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
Led by Mayo Clinic · Updated on 2026-02-13
15
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
CONDITIONS
Official Title
Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 2-21.5 years
- Confirmed diagnosis of acute lymphoblastic leukemia or lymphoma
- Planned treatment with Calaspargase Pegol (Cal-PEG)
- Informed consent obtained from parents or guardians
You will not qualify if you...
- Pre-existing coagulation disorders
- Known hypersensitivity to asparaginase products
- Liver failure
- Any acute or chronic disease that affects coagulation testing (e.g., nephrotic syndrome)
- Currently pregnant
- Use of systemic blood thinner within 48 hours prior to study blood draw
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here